The AstraZeneca share price is rising fast. Here’s what I’d do now

FTSE 100 pharmaceuticals giant AstraZeneca turned in a good set of results. Is it time to buy right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceuticals giant AstraZeneca (LSE: AZN) share price was a big gainer yesterday, rising by 5.5% from the day before as it reported a healthy set of results. Its share price is now close to all-time highs, raising the question – Is this a good time to buy AZN?

Expensive but worthy

I find it helpful to look at the price-to-earnings ratio (P/E) when share prices are rising to get a sense of how expensive the stock really is. From the looks of it, AZN sure is highly priced. Its 12-month trailing P/E is almost 43x compared to 19x for another FTSE 100 pharmaceuticals peer GlaxoSmithKline (GSK). Not to undermine GSK’s value, but I think this is a case of investors putting a premium on AZN rather than a one-off spike in its P/E, considering that it’s been maintained for some time now.

It was my top share for May, after it reported a good set of numbers and my sense was that it would rise from there on. From the time the article was published to now, the share price is up 31% and interestingly enough, the P/E is actually marginally lower than the 45x seen then. As an investor, this tells me that there are capital gains to be made even if the ratio is high, instructive as it is. Also, a high ratio doesn’t indicate that the share price will come off soon. In other words, don’t let a high P/E deter you right now because there are enough reasons that still make AZN attractive.  

Safe haven

It’s a big pharmaceuticals company in an economic environment that continues to look uncertain. A number of other defensive shares have also seen a great run-up in share prices in recent years and AZN is no exception. Its international focus also helps, since it’s not entirely vulnerable to the UK’s fortunes. In the latest earnings release, CEO Pascal Soriot noted “impressive results” in international markets like China, the US and Japan.

Performance boost

Besides this, yesterday’s results showed an 18% increase in product sales at constant exchange rate and core operating profit grew by 41% in the third quarter of 2019. The numbers look good on a year-to-date basis too. I also like that AZN has actually upgraded its sales guidance for the second straight quarter, which basically means that it is expected to continue performing going forward.

Coming back to the original question – should I buy AZN shares now, even with the price rise? I reckon that its share price will rise higher over time if things continue to go the way they are right now. Since we at the Motley Fool are concerned with long-term investments, now is as good a time as any other to buy the share. As is the nature of share prices, there will most likely be short-term dips in the near future, and that should be an opportunity to buy more of AZN. But some can be bought right away, I believe.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Calendar showing the date of 5th April on desk in a house
Investing Articles

3 things to do right now as the annual ISA deadline looms!

With the ISA contribution deadline less than three weeks away, our writer runs through a trio of things he has…

Read more »

piggy bank, searching with binoculars
Growth Shares

It could be a once-in-a-decade opportunity to buy this cheap FTSE 250 stock

Jon Smith points out a FTSE 250 stock he's weighing up as to whether it could be a rare opportunity…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

At over 10%, I couldn’t resist this FTSE 250 share’s yield!

Christopher Ruane explains why he has bought into a 10%+ yielding FTSE 250 income share that the market has lately…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Jim Cramer is bullish on NIO stock at $5! Should I buy it for my ISA?

NIO stock is trading 26% lower than a few months ago, despite just posting a historic quarter. It it time…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

How much do you really need in an ISA to earn a £20,000 passive income

Looking for ways to earn reliable passive income in an ISA? Our writer explores the path to five-figure earnings.

Read more »

Front view of aircraft in flight.
Investing Articles

The Rolls-Royce share price has now fallen 15%. Time to consider buying?

The Rolls-Royce share price is experiencing some turbulence at the moment. Is this a buying opportunity or will there be…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

Should I buy Nasdaq stock Micron for my ISA after blowout Q2 earnings?

Nasdaq tech stock Micron is generating incredible revenue growth at the moment amid the AI boom. Yet it still looks…

Read more »

Hand flipping wooden cubes for change wording" Panic" to " Calm".
Investing Articles

Is it time to dump my shares ahead of an almighty stock market crash? Nah!

How should we cope with growing fears of a stock market crash? 'Keep Calm and Carry On' worked in 1939,…

Read more »